All of us are striving to navigate the uncertainty of the COVID-19 pandemic. As the current healthcare focus is on delivering COVID-19 vaccinations, administering rapid and accurate diagnosis and providing optimal patient care, we are leveraging our expertise and global reach to provide support and continued access to critical healthcare products. With unwavering commitment, we stand united with you—now and into the future.
Our multiple domestic manufacturing facilities and extensive supplier base provide supply continuity for you and uninterrupted care for your patients.
Patient management resources
As one of the largest global medical technology companies in the world, BD is deploying its capabilities, expertise and scale to address critical health needs related to coronavirus – from diagnostic offerings to identify COVID-19, to real-time informatics and electronic surveillance technology and to essential medical devices that support patient care. This work relies on the dedication and contribution of BD employees around the world and has earned BD recognition on Fortune’s Change the World List (2020) for its fourth time in six years.
BD Track and Field Ad “Never Stopped”
65,000 people. One human hope.
COVID-19 Sample Collection
COVID-19 PCR Molecular Technology
COVID-19 Point of Care Antigen Testing
Risk of Secondary Infections in COVID-19 Patients
Infection Prevention and Control Training
Supporting COVID-19 Patients in ICUs
Tracking COVID-19 in the U.S
Supporting Research and Development of COVID-19 Treatments
Preparing for a COVID-19 Vaccination
Manufacturing
Government Partnerships
Regulatory Affairs
Partnering with Non-Government Organizations to Address COVID-19 Together
Supporting Humanitarian Organizations to Address COVID-19 Together
Serving the Community to Combat COVID-19
Updated May 2022
BD continues to closely monitor COVID-19 developments across the world as well as guidance from the U.S. Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and global health officials. We are working to protect the health and safety of BD employees while also ensuring continued availability of BD’s critical health-preserving, life-saving and diagnostic medical devices during this challenging time.
BD manufactures and sources product from multiple locations around the world. All of our global manufacturing and distribution centers are operational at this time, with the vast majority of critical-to-COVID sites operating at or near full capacity. In countries where local governments have imposed restrictions to minimize the spread of coronavirus, BD facilities continue to operate with measures in place to ensure business continuity and minimize risk of disruption to our customers.
BD continues to work closely with our key suppliers around the world that provide raw materials and components to BD manufacturing plants. We have implemented business continuity measures to mitigate the risk of potential supplier disruption, including partnering with local governments to seek “essential business” exemptions for key suppliers where necessary.
BD continues to have sufficient raw material and component inventory for the majority of products considered critical-to-COVID. Where materials or components are deemed at risk, BD activates any number of pre-approved contingency plans, including those for:
Dedicated teams continue to actively monitor our global logistics and transportation network, taking action when necessary to navigate global capacity limitations and border constraints to minimize the risk of any customer delays. We are making every effort to ensure final product is transported to distributors and customers as quickly and efficiently as possible.
For U.S. customers, an up-to-date list of products on manual inventory allocation can be found at bd.com/allocation.
BD continues to follow all state, local and federal requirements and ensure adherence to work site health and safety regulations for our essential workers. We have instituted preventative measures at our facilities to help protect employees in accordance with the CDC and government regulations. We will continue to adjust safety protocols in line with these regulations and new science emerging about virus transmission and vaccine effectiveness.
As one of the largest global medical technology companies in the world, BD is deploying our capabilities, expertise and scale to address critical health needs related to coronavirus – from our diagnostic offerings to detect SARS-CoV-2, to real-time informatics and electronic surveillance technology, to essential medical devices to support patient care. Specifically, BD:
In addition, BD and the BD Foundation has provided approximately $2.8 million in philanthropic support to help nearly a dozen of its trusted non-profit partners protect vulnerable communities during the COVID-19 pandemic. The majority of these social investments support healthcare workers in the United States, Europe, Latin America, China and India. BD volunteers also responded to the COVID-19 pandemic. Clinically-trained associates in BD sites around the world volunteered their time to augment hospital staff in communities hard-hit by COVID-19; and BD associates from a broad range of disciplines delivered virtual trainings to teach community and non-profit organizations how to contain its spread.
BD is a purpose-driven company, advancing the world of health™ by developing medical devices and sophisticated technologies that doctors, nurses, researchers and caregivers rely on to improve the lives of patients. As partners on the front lines, we’ve helped the world face down viral diseases for decades, from polio, smallpox and measles to HIV and the annual flu—and now, COVID-19.
Today, the capabilities, expertise and global reach of BD are greater than ever. In the face of the greatest healthcare challenge in generations, we rapidly mobilized to equip our healthcare partners with a comprehensive suite of technologies and solutions that have been essential to discovering more about the COVID-19 virus and its variants; diagnosing patients quickly, in a variety of settings; caring for those who are critically ill, and supporting the global vaccination campaign.
We continue to double-down on what we do best—tapping our deep resources to help solve healthcare’s biggest problems. We’ll never stop working with urgency to innovate, ensuring the front lines have what they need to address this crisis and prevent future outbreaks, and making an impact on lives around the world.
BD is a critical supplier of swabs and other sample collection products for COVID-19 and has launched multiple molecular tests, enabling clinicians to know if a patient currently has COVID-19. These molecular tests are primarily completed in a hospital lab versus an offsite reference lab, so the speed to result is two to three hours, not two to three days.
Our product teams are developing new testing options that can be quickly deployed at scale, and we have already aggressively increased production of our existing portfolio to help meet the overwhelming global demand.
Our technologies and devices are on the frontlines in the crisis, helping physicians and nurses manage medications, safely deliver drugs to patients and support advanced care needs in ICUs.
With a more detailed knowledge of immune responses, researchers have a stronger foundation to develop more effective therapies.
Our information and data technologies help health systems assess data on test results, drug inventory, hospital utilization trends and more to help form a picture of risks and responses. And as we look ahead to cautiously returning to "normal," our technologies can help detect early warning signs of re-emergence of the disease.
BD and the BD Foundation have issued nearly $2.5 million in philanthropic grants and product donations to non-profit partners that are working to protect the most vulnerable communities and individuals from the pandemic’s spread and negative impacts. BD volunteers are heeding the call, too.
Learn about our philanthropic response:
As one of the largest global medical technology companies in the world, BD is deploying our capabilities, expertise and scale to address critical health needs related to coronavirus—from our diagnostic offerings to identify COVID-19, to real-time informatics and electronic surveillance technology, to essential medical devices to support patient care.
Declared a global pandemic in March 2020, the rapid spread of COVID-19 has overwhelmed health systems and severely strained ICU capacity in hospitals. Explore how we are activating to answer the demands caused by this virus.
Used for the collection and transport of clinical specimens, including viruses.
Used to collect blood samples for serology and blood culture tests.
Used to facilitate blood sample collection from hospitalized patients who have existing access lines.
Our flocked swabs feature perpendicular nylon fibers that optimize specimen collection and elution into transport media.
Begin with a quality specimen for quality results
The BD Microtainer® contact-activated lancet is a safety-engineered device used for the fingerstick collection of blood
With (2) FDA EUA assays available and open system capability used to aid in the rapid detection of active COVID-19 infection.
Used to rapidly detect respiratory pathogens SARS-CoV-2, Flu A, Flu B, Respiratory syncytial virus (RSV) and Group A Strep.
Used to detect organisms causing bloodstream infections.
Used for delivery of IV medications required for treatment.
Used to help clinicians efficiently manage medications.
Alaris™ Pump infusion sets include various configurations and a feature that integrates our SmartSite™ needle-free valve above or below the pump module.
Reduce the risk of IV-related infections like CLABSIs with the BD portfolio of five needle-free connectors
Used to administer medications required for treatment, as well as vaccination.
Used by the pharmaceutical industry to provide drugs and vaccines in ready-to-administer formats for speed and patient safety.
Proactive venous solutions
Maintain vascular access devices
Used to deliver drugs required for treatment.
Used to drain urine from the bladder in acute care settings.
Used for fecal management in bedridden patients and administration of medications.
Used to administer immediate dialysis for patients who enter acute renal failure.
Used for results reporting and to provide access to actionable diagnostic information.
Used to help track and optimize medication use, including drug shortages.
Used for near real-time surveillance, reporting and understanding of geographic impact of pathogens, including COVID-19.
Not all products available in all geographies.
